IDEXX Laboratories, Inc. (BMV:IDXX)
Mexico · Delayed Price · Currency is MXN | Market Cap | 695.86B -26.0% |
| Revenue (ttm) | 79.56B +12.8% |
| Net Income | 19.91B +15.6% |
| EPS | 248.52 +18.4% |
| Shares Out | n/a |
| PE Ratio | 34.94 |
| Forward PE | 32.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6 |
| Open | 8,917.00 |
| Previous Close | 9,013.50 |
| Day's Range | 8,917.00 - 8,917.00 |
| 52-Week Range | 8,917.00 - 14,130.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About IDEXX Laboratories
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides com... [Read more]
Financial Performance
In 2025, IDEXX Laboratories's revenue was $4.30 billion, an increase of 10.42% compared to the previous year's $3.90 billion. Earnings were $1.06 billion, an increase of 19.33%.
Financial numbers in USD Financial StatementsNews
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm detection for broader intestinal parasite screening.
Idexx Laboratories announces acquisition of CoVetAI
IDEXX Laboratories (IDXX) announced the acquisition of CoVetAI, a leading and rapidly growing provider of AI-native ambient listening and clinical workflow software for veterinary practices. CoVet hel...
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX announces acquisition of CoVetAI to advance veterinary workflow intelligence.
IDEXX Laboratories Transcript: Barclays 24th Annual Global Financial Services Conference
Strong Q2 performance and raised guidance reflect robust recurring revenue growth and successful innovation adoption. Aging pet demographics, resilient care demand, and new diagnostic platforms like inVue Dx and Cancer Dx are driving higher utilization and market share. Commercial expansion and AI integration support long-term growth and margin improvement.
IDEXX Laboratories Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Strong Q2 performance and raised guidance reflect robust recurring revenue growth and successful innovation adoption. Diagnostic utilization per visit is rising, driven by new platforms like inVue Dx and Cancer Dx, while commercial and AI investments support long-term growth and margin expansion.
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and...
IDEXX Laboratories Transcript: Investor Day 2026
Innovation in diagnostics, software, and AI is driving sector growth, with new products like inVue Dx and Cancer Dx expanding care and recurring revenue. Strong commercial execution and global expansion support high customer loyalty and double-digit growth, while financial discipline underpins robust margins and free cash flow.
IDEXX Laboratories Slides: FY 2026
IDEXX Laboratories has posted slides in relation to its FY 2026 quarterly earnings report, which was published on August 13, 2026.
Idexx Laboratories announces launch of Catalyst proBNP Test
IDEXX Laboratories (IDXX) announced the launch of the Catalyst proBNP Test, expanding cardiac capabilities across its connected point-of-care and reference laboratory portfolio. The test measures a bi...
IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX announces Catalyst™ proBNP Test, the first and only dual-species, in-clinic diagnostic assay for cardiac assessment.
Idexx Laboratories price target lowered to $710 from $800 at Barclays
Barclays analyst Glen Santangelo lowered the firm’s price target on Idexx Laboratories (IDXX) to $710 from $800 and keeps an Overweight rating on the shares. The company reported a strong…
Idexx Laboratories price target raised to $670 from $620 at UBS
UBS analyst Andrea Alfonso raised the firm’s price target on Idexx Laboratories (IDXX) to $670 from $620 and keeps a Neutral rating on the shares.
Idexx Laboratories price target raised to $670 from $650 at Citi
Citi analyst Daniel Grosslight raised the firm’s price target on Idexx Laboratories (IDXX) to $670 from $650 and keeps a Neutral rating on the shares.
Idexx Laboratories reports Q2 EPS $4.27, consensus $3.93
Reports Q2 revenue $1.22B, consensus $1.2B. “Our Q2 results reflect the strength of our Technology for Life strategy, with continued innovation across our Catalyst, Fecal Dx, and IDEXX inVue Dx…
IDEXX Laboratories Earnings Call Transcript: Q2 2026
Q2 2026 delivered 10% revenue growth and 18% EPS growth, driven by strong CAG Diagnostics, international expansion, and innovation adoption. Full-year guidance was raised for revenue, EPS, and free cash flow conversion, with continued investments in R&D and commercial capabilities.
IDEXX Laboratories Earnings release: Q2 2026
IDEXX Laboratories released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
IDEXX Laboratories Slides: Q2 2026
IDEXX Laboratories has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
IDEXX Laboratories Quarterly report: Q2 2026
IDEXX Laboratories has published its Q2 2026 quarterly earnings report on August 4, 2026.
Idexx Laboratories raises FY26 EPS view to $14.69-$14.94 from $14.45-$14.90
2026 EPS consensus $14.66. Narrows 2026 revenue view to $4.70B-$4.745B from $4.675B-$4.760B, consensus $4.71B.
IDEXX Laboratories Announces Second Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results. Second Quarter Results The Company rep...
IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX releases 2025 Corporate Responsibility Report highlighting progress against its goals and commitments.
Idexx Laboratories price target lowered to $620 from $640 at UBS
UBS lowered the firm’s price target on Idexx Laboratories (IDXX) to $620 from $640 and keeps a Neutral rating on the shares.
IDEXX Laboratories to Release 2026 Second Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 second quarter financial results for Tue...
IDEXX Laboratories Transcript: Stifel Jaws & Paws Conference 2026
The new CEO is driving a purpose-led strategy focused on innovation, global expansion, and integrated diagnostics and software. AI and new platforms like inVue Dx and Cancer Dx are fueling growth, with strong adoption and expanding capabilities. The company expects continued momentum from a robust pipeline and sector tailwinds.
Idexx Laboratories expands Fecal Dx platform for taeniid tapeworm detection
IDEXX Laboratories (IDXX) announced the expansion of its Fecal Dx antigen testing platform with taeniid tapeworm, including Taenia and Echinococcus species. Proven to detect up to twice as many intest...